<DOC>
	<DOCNO>NCT00536107</DOCNO>
	<brief_summary>This randomize , open- label , parallel group , phase IV , multicentre study . The total number patient expect recruited 40 . These randomized patient histologically cytologically confirm adenocarcinoma histology locally advance metastatic NSCLC . Patients recruit investigational site expertise treat patient non-small cell lung cancer . The study compare gefitinib monotherapy 250 mg/day orally docetaxel 60 mg/m2 intravenously 1 hour every 3 week primary endpoint safety tolerability . The target population patient receive one prior platinum-based chemotherapy consider suitable candidate chemotherapy docetaxel . At study entry , patient randomize 1:1 basis stratify respect performance status ( 0-1 vs. 2 ) . Patients may continue receive treatment either gefitinib docetaxel disease progression , unacceptable toxicity occurrence specific criterion . An independent committee appoint perform blind review patient scan . Any assessments/visits screening perform within window plus minus 3 working day schedule visit date . If select screening evaluation do within 7 day Day 1 , Cycle 1 treatment , acceptable study entry , repeat Day 1 unless investigator believe likely significantly change . Any patient discontinues study treatment without radiological evidence disease progression ( except withdrawal consent patient ) continue objective tumor assessment every 6 week order collect information progression disease</brief_summary>
	<brief_title>Study Assess Safety/Tolerability/Efficacy Gefitinib Versus Docetaxel Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Locally advanced ( Stage IIIB ) metastatic ( Stage IV ) NSCLC , amenable curative surgery radiotherapy Treatment one prior chemotherapy regimen , must platinum based* *Patients must demonstrate radiological clinical progression since completion previous chemotherapy regimen . Adequate hepatic function , define BOTH bilirubin &lt; upper limit reference range ( ULRR ) AND `` Eligible '' combination transaminase ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ) alkaline phosphatase ( ALP ) : Not Eligible : AST ALT &gt; 5xULRR , 1.5xULRR &lt; AST ALT &lt; 5xULRR ALP &gt; ULRR , 1xULRR &lt; AST ALT &lt; 1.5xULRR ALP &gt; 2.5xULRR , AST ALT &lt; = ULRR ALP &gt; 5xULRR For information please refer TAXOTERE® ( docetaxel ) prescribe information Prior therapy gefitinib EGFR TK inhibitor ( HER1 receptor inhibitors/small molecule monoclonal antibody therapy ) Prior docetaxel treatment NSCLC Patients preexist peripheral neuropathy ³ grade 2 ( NCI CTCAE criterion ) Past medical history interstitial lung disease , drug induce interstitial disease , radiation pneumonitis require steroid treatment evidence clinically active interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Locally Advanced Metastatic NSCL Cancer</keyword>
</DOC>